메뉴 건너뛰기




Volumn 4, Issue 5 SUPPL., 2007, Pages 5-7

The chemotherapy-naive patient with metastatic colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

EID: 34249776052     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (17)
  • 1
    • 0034712536 scopus 로고    scopus 로고
    • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
    • Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
    • (2000) Lancet , vol.355 , pp. 1041-1047
    • Douillard, J.Y.1    Cunningham, D.2    Roth, A.D.3
  • 2
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF, at al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
    • (2004) J Clin Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3    at al4
  • 3
    • 2542615200 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    • Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
    • (2004) N Engl J Med , vol.350 , pp. 2343-2351
    • Andre, T.1    Boni, C.2    Mounedji-Boudiaf, L.3
  • 4
    • 1342290189 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    • Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
    • (2004) J Clin Oncol , vol.22 , pp. 229-237
    • Tournigand, C.1    Andre, T.2    Achille, E.3
  • 5
    • 24644457747 scopus 로고    scopus 로고
    • Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
    • Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
    • (2005) J Clin Oncol , vol.23 , pp. 4866-4875
    • Colucci, G.1    Gebbia, V.2    Paoletti, G.3
  • 6
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 7
    • 34249293549 scopus 로고    scopus 로고
    • Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC)
    • Presented at the, January 19-21, Orlando, Fla. Abstract 238
    • Saltz LB, Clarke S, Diaz-Rubio E, et at. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2007; January 19-21, 2007; Orlando, Fla. Abstract 238.
    • (2007) American Society of Clinical Oncology Gastrointestinal Cancer Symposium
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3    et at4
  • 8
    • 34249794358 scopus 로고    scopus 로고
    • Eloxatin [package insert, Bridgewater, NJ: Sanofi-Aventis; 2006
    • Eloxatin [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2006.
  • 9
    • 34249819142 scopus 로고    scopus 로고
    • Camptosar [package insert, New York, NY: Pfizer Inc/Pharmacia & Upjohn Co
    • Camptosar [package insert]. New York, NY: Pfizer Inc/Pharmacia & Upjohn Co.
  • 10
    • 78649965752 scopus 로고    scopus 로고
    • National Cancer Institute, Available at:, Accessed May 4
    • National Cancer Institute. Colon Cancer (PDQ): Treatment. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/colon/ HealthProfessional/ page9. Accessed May 4, 2007.
    • (2007) Colon Cancer (PDQ): Treatment
  • 11
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3    Schmoll, H.J.4
  • 12
    • 33644825856 scopus 로고    scopus 로고
    • Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
    • Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441-9442.
    • (2005) J Clin Oncol , vol.23 , pp. 9441-9442
    • Grothey, A.1    Sargent, D.2
  • 13
    • 0345403552 scopus 로고    scopus 로고
    • Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
    • Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
    • (1998) J Clin Oncol , vol.16 , pp. 418-426
    • Kohne, C.H.1    Schoffski, P.2    Wilke, H.3
  • 14
    • 2642642086 scopus 로고    scopus 로고
    • Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? a phase II study
    • Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? a phase II study. Oncology 1998;55:320-325.
    • (1998) Oncology , vol.55 , pp. 320-325
    • Hartmann, J.T.1    Kohne, C.H.2    Schmoll, H.J.3    Daikeler, T.4    Kanz, L.5    Bokemeyer, C.6
  • 15
    • 17644382288 scopus 로고    scopus 로고
    • Critical evaluation of current treatments in metastatic colorectal cancer
    • Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005;10:250-261.
    • (2005) Oncologist , vol.10 , pp. 250-261
    • Venook, A.1
  • 16
    • 33749852995 scopus 로고    scopus 로고
    • Therapy for metastatic colorectal cancer
    • Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981-987.
    • (2006) Oncologist , vol.11 , pp. 981-987
    • Goldberg, R.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.